Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F3 | P13726 | 18/20 | 0.48 |
| ▸ | F2 | P00734 | 2/20 | 0.48 |
| ▸ | F10 | P00742 | 1/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.45 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26088542 | 0.89 | DAO (0.43) | F3F2F10PRSS1PRSS2 | |
| SCHEMBL14760384 | 0.82 | KDM4E (0.43) | F3F2F10PRSS1PRSS2 | |
| SCHEMBL8732516 | 0.82 | KDR (0.53) | — | |
| SCHEMBL29871364 | 0.78 | F3 (0.48) | F3F2F10DAO | |
| SCHEMBL3837963 | 0.78 | F3 (0.48) | F3F2F10DAO | |
| SCHEMBL26086683 | 0.76 | F3 (0.50) | F3F2F10PRSS1PRSS2 | |
| SCHEMBL26089278 | 0.74 | KDM4E (0.68) | F3PDE10A | |
| SCHEMBL28317738 | 0.74 | TRPA1 (0.50) | F3F2F10PRSS1PRSS2 | |
| SCHEMBL8878252 | 0.73 | CYP19A1 (0.63) | F3F2DAO | |
| SCHEMBL26086870 | 0.72 | F3 (0.47) | F3F2F10PRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577242-B2 | Pyrrolopyridine and imidazopyridine antiviral compounds | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2026-03-17 | — | — | US | disclosed |
| US-20230130598-A1 | PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-04-27 | — | — | US | disclosed |
| US-20230130598-A1 | PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-04-27 | — | — | US | disclosed |
| EP-4110777-A1 | PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS | Katholieke Universiteit Leuven, K.U.Leuven R&D (BE) | 2023-01-04 | — | — | EP | disclosed |
| CN-115175909-A | Pyrrolopyridine and imidazopyridine antiviral compounds | 鲁汶天主教大学 | 2022-10-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230130598-A1 | PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS | SARS1, TPI1, TPMT | F3 850/4885F2 673/4885F10 3930/4885 |
| US-12577242-B2 | Pyrrolopyridine and imidazopyridine antiviral compounds | SARS1, TPMT, ZC3HAV1 | F3 4492/4885F2 2869/4885F10 3777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.